These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Orphan drug development in the United States. Groft SC CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306 [TBL] [Abstract][Full Text] [Related]
4. Orphan drug development for the treatment of rare chronic diseases. Moore ES Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218 [No Abstract] [Full Text] [Related]
6. Orphan drugs: the question of products liability. Scharf SF Am J Law Med; 1985; 10(4):491-513. PubMed ID: 3911776 [TBL] [Abstract][Full Text] [Related]
7. Lucrative niches: how drugs for rare diseases became lifeline for companies. Anand G Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531 [No Abstract] [Full Text] [Related]
8. The Pharmaceutical Manufacturers Association Commission on Drugs for Rare Diseases. Goldstein GS Prog Clin Biol Res; 1985; 197():35-9. PubMed ID: 4070297 [No Abstract] [Full Text] [Related]
9. Orphan Drug Act on congressional agenda. von Oehsen WH Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123 [TBL] [Abstract][Full Text] [Related]
10. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act. Arno PS; Bonuck K; Davis M Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947 [TBL] [Abstract][Full Text] [Related]
11. Rare diseases: identifying needs. Report of the National Commission on Orphan Diseases. Groft SC Am Pharm; 1990 Apr; NS30(4):33-40. PubMed ID: 2321528 [No Abstract] [Full Text] [Related]
12. [Orphan drugs]. Kolár J; Chalabala M; Srámková H Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591 [TBL] [Abstract][Full Text] [Related]
13. The fuel to run the orphan drug engine: a medical school-based Orphan Disease Center Program. Brewer GJ Prog Clin Biol Res; 1985; 197():123-38. PubMed ID: 4070287 [No Abstract] [Full Text] [Related]
14. Problems associated with developing orphan drugs into available therapy. Van Woert MH Prog Clin Biol Res; 1985; 197():171-3. PubMed ID: 4070291 [No Abstract] [Full Text] [Related]
15. Orphan Drugs Information Center. FDA Drug Bull; 1985 Apr; 15(1):9-10. PubMed ID: 3996806 [No Abstract] [Full Text] [Related]
16. Drugs for rare diseases: mixed assessment in Europe. Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539 [TBL] [Abstract][Full Text] [Related]
20. Orphan products development and some methods for maximizing the usefulness of research on rare diseases. Finkel MJ Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285 [No Abstract] [Full Text] [Related] [Next] [New Search]